The role of Crooke’s changes in recurrence and remission after gamma knife radiosurgery
The objective of this study is to evaluate the role of Crooke’s changes (CC) in normal the peri-tumoral anterior pituitary gland, in patients with Cushing’s disease (CD) with a histopathological confirmed corticotroph adenoma, and determine if there is any difference in the recurrence and remission rates in CD patients after treatment with Gamma Knife Radiosurgery (GKRS).
All patients treated with GKRS for CD from 2005 to 2016 at our institution were identified. Patients had a confirmed adrenocorticotropic (ACTH)-secreting adenoma, i.e. corticotroph adenoma, and normal pituitary gland included in the surgical specimen, and specimens were stained with hematoxylin and eosin and also immunostaining for cytokeratin and ACTH. Statistical analyses were performed in a total of 61 patients who met the inclusion criteria. Additionally, we analyzed 20 patients in each group, with and without CC, after they were matched in a propensity score fashion.
Endocrine remission defined as, a normal 24 h urine free cortisol while off suppressive medication, occurred in 48 patients (78.7%), with 76.9% in those with CC and 81.8% in those without CC. There was no statistical significant difference between the two groups in regarding remission (p = 0.312) or recurrence (p = 0.659) in either the unmatched or matched cohorts.
The presence or absence of CC in normal pituitary gland does not appear to confer a lower rate of remission or a higher rate of recurrence after GKRS. Patients with pituitary corticotroph adenomas that present with CC features may be well served by Stereotactic radiosurgery (SRS).
KeywordsGamma knife radiosurgery Pituitary adenoma Cushing’s disease Crooke’s changes Neuropathology Stereotactic radiosurgery
Compliance with ethical standards
Conflict of interest
All authors certify that they do not have any conflict of interest.
The study was approved by the Institutional Review Board (IRB) of University of Virginia (UVA).
This is a retrospective study and informed consent was not required.
- 1.Crooke A (1935) Change in the basophil cells of the pituitary gland common to conditions which exhibit the syndrome attributed to basophil adenoma. J Pathol Bacteriol 41:339–349Google Scholar
- 10.Mohammed S, Kovacs K, Mason W, Smyth H, Cusimano MD (2009) Use of temozolomide in aggressive pituitary tumors: case report. Neurosurgery 64(4):E773-774. https://doi.org/10.1227/01.NEU.0000339115.12803.4E Google Scholar
- 11.Takeshita A, Inoshita N, Taguchi M, Okuda C, Fukuhara N, Oyama K, Ohashi K, Sano T, Takeuchi Y, Yamada S (2009) High incidence of low O(6)-methylguanine DNA methyltransferase expression in invasive macroadenomas of Cushing’s disease. Eur J Endocrinol 161(4):553–559. https://doi.org/10.1530/EJE-09-0414 PubMedGoogle Scholar
- 12.Kovacs GL, Goth M, Rotondo F, Scheithauer BW, Carlsen E, Saadia A, Hubina E, Kovacs L, Szabolcs I, Nagy P, Czirjak S, Hanzely Z, Kovacs K, Horvath E, Korbonits M (2013) ACTH-secreting Crooke cell carcinoma of the pituitary. Eur J Clin Investig 43(1):20–26. https://doi.org/10.1111/eci.12010 Google Scholar
- 17.Mehta GU, Ding D, Patibandla MR, Kano H, Sisterson N, Su YH, Krsek M, Nabeel AM, El-Shehaby A, Kareem KA, Martinez-Moreno N, Mathieu D, McShane B, Blas K, Kondziolka D, Grills I, Lee JY, Martinez-Alvarez R, Reda WA, Liscak R, Lee CC, Lunsford LD, Vance ML, Sheehan JP (2017) Stereotactic radiosurgery for cushing disease: results of an international, multicenter study. J Clin Endocrinol Metab 102(11):4284–4291. https://doi.org/10.1210/jc.2017-01385 PubMedGoogle Scholar
- 19.Hassan-Smith ZK, Sherlock M, Reulen RC, Arlt W, Ayuk J, Toogood AA, Cooper MS, Johnson AP, Stewart PM (2012) Outcome of cushing’s disease following transsphenoidal surgery in a single center over 20 years. J Clin Endocrinol Metab 97(4):1194–1201. https://doi.org/10.1210/jc.2011-2957 PubMedGoogle Scholar
- 20.Pouratian N, Prevedello DM, Jagannathan J, Lopes MB, Vance ML, Laws ER Jr (2007) Outcomes and management of patients with Cushing’s disease without pathological confirmation of tumor resection after transsphenoidal surgery. J Clin Endocrinol Metab 92(9):3383–3388. https://doi.org/10.1210/jc.2007-0208 PubMedGoogle Scholar
- 22.Valassi E, Biller BM, Swearingen B, Pecori Giraldi F, Losa M, Mortini P, Hayden D, Cavagnini F, Klibanski A (2010) Delayed remission after transsphenoidal surgery in patients with Cushing’s disease. J Clin Endocrinol Metab 95(2):601–610. https://doi.org/10.1210/jc.2009-1672 PubMedPubMedCentralGoogle Scholar
- 23.Patil CG, Veeravagu A, Prevedello DM, Katznelson L, Vance ML, Laws ER Jr (2008) Outcomes after repeat transsphenoidal surgery for recurrent Cushing’s disease. Neurosurgery 63(2):266–270. https://doi.org/10.1227/01.NEU.0000313117.35824.9F PubMedGoogle Scholar
- 27.Colin P, Jovenin N, Delemer B, Caron J, Grulet H, Hecart AC, Lukas C, Bazin A, Bernard MH, Scherpereel B, Peruzzi P, Nakib I, Redon C, Rousseaux P (2005) Treatment of pituitary adenomas by fractionated stereotactic radiotherapy: a prospective study of 110 patients. Int J Radiat Oncol Biol Phys 62(2):333–341. https://doi.org/10.1016/j.ijrobp.2004.09.058 PubMedGoogle Scholar
- 28.Sheehan JP, Niranjan A, Sheehan JM, Jane JA Jr, Laws ER, Kondziolka D, Flickinger J, Landolt AM, Loeffler JS, Lunsford LD (2005) Stereotactic radiosurgery for pituitary adenomas: an intermediate review of its safety, efficacy, and role in the neurosurgical treatment armamentarium. J Neurosurg 102(4):678–691. https://doi.org/10.3171/jns.2005.102.4.0678 PubMedGoogle Scholar